ReviewFrontiers in immunology2020
Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated γδ T lymphocytes.Journal of neuro-oncology · 2021Pooled it
- Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms.The Journal of dermatology · 2026Review
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.Antibody therapeutics · 2026Article
- Multi-omics and machine learning integration of diverse cell death pathways optimize risk stratification and inform drug therapy in Wilms tumor.Discover oncology · 2026Article
- CDC42SE1 as a novel prognostic biomarker with immunomodulatory associations in breast invasive carcinoma.Discover oncology · 2026Article
- Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance.Molecular cancer · 2026Review
- Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.Journal for immunotherapy of cancer · 2026Article
- Early On-Treatment Expansion of Peripheral γδT Cells as a Noninvasive Biomarker of Response to Programmed Death-1 Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer.Cancer management and research · 2026Article
- Article
- γδT cells, a key subset of T cell for cancer immunotherapy.Frontiers in immunology · 2025Review
- Thymoma and thymic carcinoma.Indian journal of thoracic and cardiovascular surgery · 2024Article
- The Evolving Portrait of γδ TCR Recognition Determinants.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- Article
- Key players of immunosuppression in epithelial malignancies: Tumor-infiltrating myeloid cells and γδ T cells.Cancer reports (Hoboken, N.J.) · 2024Review
- Landscape of unconventional γδ T cell subsets in cancer.Molecular biology reports · 2024Review
- Isolation and expansion of pure and functional γδ T cells.Frontiers in immunology · 2024Article
- Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment.Molecular cancer · 2023Review
- Review
- BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expandedOncoimmunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor immune microenvironment contributes to tumor initiation, progression and response to therapy. Among the immune cell subsets that play a role in the tumor microenvironment, innate-like T cells that express T cell receptors composed of γ and δ chains (γδ T cells) are of particular interest. Indeed, γδ T cells contribute to the immune response against many cancers, notably through their powerful effector functions that lead to the elimination of tumor cells and the recruitment of other immune cells. However, their presence in the tumor microenvironment has been associated with poor prognosis in various solid cancers (breast, colon and pancreatic cancer), suggesting that γδ T cells also display pro-tumor activities. In this review, we outline the current evidences of γδ T cell pro-tumor functions in human cancer. We also discuss the factors that favor γδ T cell polarization toward a pro-tumoral phenotype, the characteristics and functions of such cells, and the impact of pro-tumor subsets on γδ T cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.